Head-to-head · WeighScore
ElixaMD vs Vita Bella
The verdict
Vita Bella takes it — 64.9/100 to 63.7/100, but only just.
Vita Bella grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vita Bella is a Nevada-based telehealth membership platform (Vita Bella Health, LLC) that offers compounded GLP-1 weight-loss medications alongside hormone therapy, peptides, sexual-wellness and anti-aging… ElixaMD is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | ElixaMD | Vita Bella |
|---|---|---|
| WeighScore | 63.7/100 | 64.9/100 |
| Grade | C | C |
| Scorecard rank | #251 | #233 |
| Semaglutide | $179/mo (starting dose, first-month rate, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | $159/mo (2.5 mg dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 46 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #251 · C
Strengths
- Compounded semaglutide from $179 first month with free shipping, no membership, no contract, and no insurance required
- Genuinely all-inclusive: 1:1 physician guidance, free dietician visits and care coaching, 24/7 support, and an all-in-one patient portal
- Names its compounding pharmacies (RedRock Pharmacy, Beaker Pharmacy) — more transparent than most compounded sellers
- HSA/FSA eligible; full legal suite (Terms, Privacy, Privacy Practices, Refund, Medical Consent, California Bill of Rights)
Where it loses points
- $179 is a first-month/intro price — ongoing monthly cost is higher (tiers to ~$249-$299)
- Compounded semaglutide is not FDA-approved (the site discloses this) — not brand Wegovy or Ozempic
- Appears to offer compounded semaglutide only — tirzepatide is not advertised
- Displays a generic LegitScript Certified badge but no verifiable seal/listing; state-availability list not published
Graded #233 · C
Strengths
- Offers both compounded semaglutide (from $109/mo) and tirzepatide (from $159/mo) at member pricing, with supplies and a B-6 add-in included
- Genuine LegitScript-certified website (seal #4395819) and a clearly disclosed legal entity, Vita Bella Health, LLC (Nevada)
- Broad access: care published for 46 states plus Washington, D.C., and HSA cards are accepted
- Fully remote telehealth with video provider consults and quarterly provider check-ins included in the membership
- Medications dispensed by US FDA-inspected compounding pharmacies; ondansetron for nausea provided at no extra charge
Where it loses points
- Advertised $109-$159 medication prices require a separate $129/mo membership plus a one-time $99 consult, pushing true cost to ~$238-288/mo
- Three-month minimum commitment before it renews month-to-month; no refunds on medications and all sales are final
- Compounding pharmacy partners are not named anywhere on the site — a transparency gap
- Compounded semaglutide and tirzepatide are not FDA-approved; only the dispensing pharmacies are described as FDA-inspected
- Disputes are subject to binding arbitration with a class-action waiver, governed by Nevada law (Las Vegas jurisdiction)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.